文献速递其他结缔组织病

自体造血干细胞移植与系统性硬化症健康相关生活质量显著改善相关

Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Health-Related Quality of Life.
PubMed 文献 · Arthritis Rheumatol · 2020-12-29

这项回顾性研究比较了41例接受自体造血干细胞移植的系统性硬化症患者与65例符合移植指征但接受常规治疗的患者。移植组SF-36躯体成分评分在第1年(平均差7.02分,P=0.001)和第7年(平均差14.40分,P=0.03)均高于常规治疗组,HAQ评分在随访期间也显著更优;两组SF-36心理成分评分无差异。

要点

  • 自体HSCT组SF-36躯体成分评分在第1年和第7年随访时均显著高于常规治疗组。
  • 自体HSCT组HAQ评分在随访期间显著优于常规治疗组(第1年P<0.001)。
  • 两组SF-36心理成分评分在基线及随访期间均无差异。

核心结论

  • 自体造血干细胞移植与系统性硬化症患者健康相关生活质量的躯体方面显著且持续改善相关,心理方面未见差异。

研究设计与样本

  • 回顾性研究,比较41例接受自体HSCT的SSc患者与65例符合移植指征但接受常规治疗的SSc患者,采用线性模型并校正基线评分及治疗与删失的逆概率权重。

主要发现

  • SF-36躯体成分评分在自体HSCT组第1年随访时平均±SEM高7.02±1.94分(P=0.001),第7年高14.40±6.16分(P=0.03)。
  • HAQ评分自体HSCT组随访期间显著更优,第1年较基线平均±SEM差-0.57±0.13(P<0.001),第7年-0.94±0.49(P=0.07)。
  • SF-36心理成分评分两组在基线及随访期间均无差异。

临床怎么用

  • 对于符合移植指征的系统性硬化症患者,自体HSCT可能带来躯体健康相关生活质量的长期获益,可作为综合评估的参考信息。

局限性

  • 为回顾性研究设计,样本量有限(移植组41例、常规治疗组65例),结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the magnitude, domains, and duration of change in health-related quality of life (HRQoL) in patients with systemic sclerosis (SSc) who underwent autologous hematopoietic stem cell transplantation (HSCT) as compared to SSc patients with similar characteristics who did not undergo autologous HSCT. METHODS: The study was designed as a retrospective study comparing SSc patients who underwent autologous HSCT and SSc patients who met the criteria for transplantation but were treated with conventional care. Outcomes included scores on the 36-item Short Form (SF-36) health survey and the Health Assessment Questionnaire (HAQ) and its disease-specific symptom scales. Differences in scores between the groups were compared using linear models, adjusting for baseline scores and inverse probability of treatment and censoring weights. RESULTS: In total, 41 SSc patients who underwent autologous HSCT and 65 SSc patients treated with conventional care were compared. In marginal linear weighted models, the SF-36 physical component summary score was a mean ± SEM 7.02 ± 1.94 points higher at the first annual visit (P = 0.001) and 14.40 ± 6.16 points higher at the seventh annual visit (P = 0.03) in patients treated with autologous HSCT compared to the conventional care group. HAQ scores were significantly better in the autologous HSCT group compared to the conventional care group during follow-up (mean ± SEM difference from baseline -0.57 ± 0.13 [P < 0.001] at the first annual visit and -0.94 ± 0.49 [P = 0.07] at the seventh annual visit). There were no differences in the SF-36 mental component summary scores between the 2 groups either at baseline or during follow-up. CONCLUSION: This study provides robust complementary HRQoL data, including overall and event-free survival data, to expand on the standard repertoire of biomedical variables, thus potentially supporting the physical benefits of autologous HSCT in patients with SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Maltez N, Puyade M, Wang M, et al. Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Health-Related Quality of Life. Arthritis Rheumatol. 2020. PMID: 32909693. doi:10.1002/art.41519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。